Heramed Ltd
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the … Read more
Heramed Ltd (HMD) - Net Assets
Latest net assets as of June 2025: AU$379.12K AUD
Based on the latest financial reports, Heramed Ltd (HMD) has net assets worth AU$379.12K AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.04 Million) and total liabilities (AU$658.25K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$379.12K |
| % of Total Assets | 36.55% |
| Annual Growth Rate | 8.82% |
| 5-Year Change | -13.63% |
| 10-Year Change | N/A |
| Growth Volatility | 534.92 |
Heramed Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Heramed Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Heramed Ltd (2016–2024)
The table below shows the annual net assets of Heramed Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$1.72 Million | +267.50% |
| 2023-12-31 | AU$466.70K | -83.87% |
| 2022-12-31 | AU$2.89 Million | +554.87% |
| 2021-12-31 | AU$441.88K | -77.75% |
| 2020-12-31 | AU$1.99 Million | -16.88% |
| 2019-12-31 | AU$2.39 Million | -28.81% |
| 2018-12-31 | AU$3.36 Million | +1562.41% |
| 2017-12-31 | AU$201.88K | -76.85% |
| 2016-12-31 | AU$872.17K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Heramed Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2608135609.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$24.10 Million | 1404.97% |
| Other Comprehensive Income | AU$6.29 Million | 366.93% |
| Total Equity | AU$1.72 Million | 100.00% |
Heramed Ltd Competitors by Market Cap
The table below lists competitors of Heramed Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wider Planet Inc.
KQ:321820
|
$18.44 Million |
|
Ananda Development Public Company Limited
BK:ANAN
|
$18.46 Million |
|
SOL-GEL TECHN. IS-10
F:4SG
|
$18.46 Million |
|
Ocumetics Technology Corp
OTCQB:OTCFF
|
$18.47 Million |
|
Intrusion Inc
NASDAQ:INTZ
|
$18.44 Million |
|
Yung Zip Chemical Ind Co Ltd
TWO:4102
|
$18.43 Million |
|
I.Kloukinas-I.Lappas S.A
AT:KLM
|
$18.43 Million |
|
Advanced Credit Technologies Inc
PINK:CLOQ
|
$18.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heramed Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 466,699 to 1,715,113, a change of 1,248,414 (267.5%).
- Net loss of 3,398,265 reduced equity.
- Share repurchases of 7,082,830 reduced equity.
- New share issuances of 7,082,833 increased equity.
- Other comprehensive income increased equity by 1,270,625.
- Other factors increased equity by 3,376,051.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-3.40 Million | -198.14% |
| Share Repurchases | AU$7.08 Million | -412.97% |
| Share Issuances | AU$7.08 Million | +412.97% |
| Other Comprehensive Income | AU$1.27 Million | +74.08% |
| Other Changes | AU$3.38 Million | +196.84% |
| Total Change | AU$- | 267.50% |
Book Value vs Market Value Analysis
This analysis compares Heramed Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.49x to 13.02x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | AU$0.01 | AU$0.04 | x |
| 2017-12-31 | AU$0.00 | AU$0.04 | x |
| 2018-12-31 | AU$0.04 | AU$0.04 | x |
| 2019-12-31 | AU$0.03 | AU$0.04 | x |
| 2020-12-31 | AU$0.02 | AU$0.04 | x |
| 2021-12-31 | AU$0.00 | AU$0.04 | x |
| 2022-12-31 | AU$0.01 | AU$0.04 | x |
| 2023-12-31 | AU$0.00 | AU$0.04 | x |
| 2024-12-31 | AU$0.00 | AU$0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heramed Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -198.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1507.04%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.62x
- Recent ROE (-198.14%) is above the historical average (-260.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -235.57% | 0.00% | 0.00x | 1.98x | AU$-2.14 Million |
| 2017 | -392.23% | 0.00% | 0.00x | 6.18x | AU$-812.02K |
| 2018 | -86.78% | -4880.82% | 0.01x | 1.27x | AU$-3.25 Million |
| 2019 | -132.54% | -2152.08% | 0.04x | 1.51x | AU$-3.41 Million |
| 2020 | -169.14% | -8500.28% | 0.01x | 1.60x | AU$-3.56 Million |
| 2021 | 0.00% | -6822.27% | 0.02x | 0.00x | AU$-5.70 Million |
| 2022 | -169.25% | -2261.58% | 0.05x | 1.45x | AU$-5.17 Million |
| 2023 | -964.81% | -1089.77% | 0.21x | 4.32x | AU$-4.55 Million |
| 2024 | -198.14% | -1507.04% | 0.08x | 1.62x | AU$-3.57 Million |
Industry Comparison
This section compares Heramed Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $14,750,885
- Average return on equity (ROE) among peers: -315.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heramed Ltd (HMD) | AU$379.12K | -235.57% | 1.74x | $18.44 Million |
| 4DMEDICAL Ltd (4DX) | $926.64K | -85.93% | 0.18x | $1.03 Billion |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $2.37 Million |
| Aroa Biosurgery Ltd (ARX) | $-22.65 Million | 0.00% | 0.00x | $92.74 Million |
| Atomo Diagnostics Ltd (AT1) | $34.48 Million | -26.73% | 0.05x | $8.96 Million |
| Control Bionics Ltd (CBL) | $6.09 Million | -15.97% | 0.04x | $4.98 Million |
| Cardiex Ltd (CDX) | $3.03 Million | -101.61% | 0.73x | $4.25 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $13.08 Million |
| Cochlear Ltd (COH) | $75.42 Million | 53.19% | 1.13x | $7.01 Billion |
| Cleo Diagnostics Ltd (COV) | $5.83 Million | -68.54% | 0.19x | $23.47 Million |
| Conneqt Health Limited (CQT) | $633.50K | -2871.98% | 13.72x | $4.66 Million |